04 October 2021
PRESS RELEASE
BioMAdvanced Diagnostics accelerates further its development and opens the position of Quality Manager to be filled ideally before the end of the year. Please check the Career page of our websites and/or our LinkedIn company page for further details.
As a reminder, BioMAdvanced Diagnostics, a BioTech/MedTech start-up from Nantes, a spinoff from the CRTI laboratory (Centre de Recherche en Transplantation et Immunologie, UMR 1064, INSERM – University of Nantes) and from the University Hospital (CHU) of Nantes, which aims to offer companion molecular diagnostic tests and biomarkers in connection with the immune response of patients. On the basis of a common technological base, the first applications will concern: 1) improving the follow-up of patients who have received a kidney or lung transplant, and 2) determining the best drug to administer to patients with ulcerative colitis (UC). These tests are designed to be integrated into standard diagnostic and treatment protocols, easy to use by staff caring for targeted patients. Predictive scores are produced using algorithms based on the combination of signatures from the expression of selected genes and clinical parameters.